Investor: 'Pharma Bro' Reported Too-Good-To-Be-True Returns | NECN
National & International News
The day’s top national and international news

Investor: 'Pharma Bro' Reported Too-Good-To-Be-True Returns

Martin Shkreli became a pariah in 2015 after his drug company raised the price of a life-saving medicine from $13.50 to $750 per pill

    processing...

    NEWSLETTERS

    (Published Monday, June 26, 2017)

    An investor who put $300,000 into one of "Pharma Bro" Martin Shkreli's health care industry hedge fund testified Thursday that he reported eye-popping returns before abruptly shutting down the fund and ducking her demands to get her money back.

    Prosecutors say the account shows Sarah Hassan was a victim of a scam orchestrated by the impish former pharmaceutical CEO and social media provocateur, even though Hassan ultimately recouped the money in a settlement that included a stock windfall.

    "To hear over a year later that the cash was gone, it was upsetting," Sarah Hassan testified as the first witness at Shkreli's securities fraud trial in federal court in Brooklyn. "I saw that as being my cash. It was just not right."

    Shkreli, 34, became a pariah in 2015 after a drug company he founded, Turing Pharmaceuticals, spent $55 million for the U.S. rights to sell a life-saving medicine called Daraprim and promptly raised the price from $13.50 to $750 per pill.

    The spotlight intensified later that year with his arrest on charges — unrelated to Daraprim — focusing on a pair of failed hedge funds he started by luring in wealthy investors with lies about the worth of his portfolio. After he lost investors' money through bad trades, he secretly looted Retrophin, another biotech company where he was CEO, for $10 million to pay back his disgruntled clients, prosecutors said.

    Hassan, daughter of former Bausch & Lomb chairman Fred Hassan, told jurors she agreed to have dinner with Skhreli after a friend of her father's told her he was "a rising star in the hedge fund world," she said, adding that Shkreli claimed to manage $40 million. She said she was "thrilled" when he reported in September 2012 email she made nearly a $135,000 profit.

    Despite never receiving formal account statements, "I trusted him and I trusted the numbers," she said.

    In another email to all investors, Shkreli announced he was using all the assets in the fund to launch Retrophin. When she tried to get her investment back, he stalled for months before she finally agreed to a settlement for $400,000 cash and stock shares she sold for $900,000 once the company went public, she said.

    On cross-examination, defense attorney Benjamin Brafman pressed on how his client had harmed her, aside from being a pain to deal with.

    "I know it was frustrating — trust me, I've dealt with him — but at the end of the day, you had a successful agreement in which you more than tripled your money, correct?" he said.

    She agreed. But she also said that until the settlement, she had to live with the fear that she lost her money.

    Along with the price-gouging scandal, Shkreli has become notorious for bragging about himself and trolling critics on social media. A posting on his Facebook page on Thursday assailed news accounts of jury selection that highlighted how prospective jurors got dismissed for making nasty comments about him. He wrote: "Lying media corporate drones love to lie for their shareholders."